Price$2.35-0.21 (-8.20%)
01:30 PM07:45 PM
News · 26 weeks36+150%
2025-12-282026-06-21
Mix2090d
- Insider9(45%)
- SEC Filings6(30%)
- Other3(15%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 8-K filed by Codexis Inc.8-K - CODEXIS, INC. (0001200375) (Filer)
- INSIDERSEC Form 4 filed by Director Parker H Stewart4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Cynthia4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Richards Christos4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith David V4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Singhvi Rahul4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Martinborough Esther4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Dilly Stephen George4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director De Vre Raymond4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERDirector De Vre Raymond sold $6,174 worth of shares (2,605 units at $2.37), decreasing direct ownership by 3% to 84,811 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- PRCodexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USAREDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while addressing key industry challenges in scalability and sustainability. At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control
- SECSEC Form 10-Q filed by Codexis Inc.10-Q - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Reports First Quarter 2026 Financial ResultsReports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis® Manufacturing Platform enables control over phos
- PRCodexis to share RNA manufacturing advances at TIDES USAREDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston. As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry, improved ligation efficiency and process performance, a
- SECSEC Form DEFA14A filed by Codexis Inc.DEFA14A - CODEXIS, INC. (0001200375) (Filer)
- SECSEC Form DEF 14A filed by Codexis Inc.DEF 14A - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis to Report First Quarter 2026 Financial Results on May 7REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-87
- SECSEC Form 8-K filed by Codexis Inc.8-K - CODEXIS, INC. (0001200375) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.SCHEDULE 13G/A - CODEXIS, INC. (0001200375) (Subject)
- SECSEC Form 10-K filed by Codexis Inc.10-K - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsQ4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis
- SECSEC Form SCHEDULE 13G filed by Codexis Inc.SCHEDULE 13G - CODEXIS, INC. (0001200375) (Subject)
- PRCodexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing PlatformREDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to deliver meaningfu
CDXS FAQ
7 questionsWhat does Codexis Inc. do?
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases...Where does CDXS stock trade?
Codexis Inc. (CDXS) is listed on NASDAQ.What sector and industry is CDXS in?
Codexis Inc. operates in the Industrials sector, Major Chemicals industry.When did Codexis Inc. go public?
Codexis Inc. (CDXS) completed its IPO in 2010.What are analysts saying about CDXS?
Codexis Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Hold on 2024-08-19.What companies are similar to CDXS?
Notable peers in the same industry include LIN (Linde plc), APD (Air Products and Chemicals Inc.), DOW (Dow Inc.), DD (DuPont de Nemours Inc.), IFF (International Flavors & Fragrances Inc.). Compare CDXS side-by-side with any of them on Quantisnow.How can I track CDXS on Quantisnow?
Quantisnow aggregates Codexis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDXS to receive live email and push alerts on every new disclosure.